Literature DB >> 20122868

T cell receptor gene therapy: strategies for optimizing transgenic TCR pairing.

Coen Govers1, Zsolt Sebestyén, Miriam Coccoris, Ralph A Willemsen, Reno Debets.   

Abstract

T cell receptor (TCR) gene therapy provides patients with autologous T cells that are genetically engineered with TCRalphabeta chains and constitutes a promising approach for the treatment of tumors and virus infections. Among the current challenges of TCR gene therapy is the optimization of TCRalpha and beta transgene pairing to enhance the functional avidity of therapeutic T cells. Recently, various genetically modified TCRs have been developed that enhance TCR pairing and minimize mispairing, i.e. pairing between transgenic and endogenous TCR chains. Here, we classify such receptors according to their CD3-dependence for surface expression and review their abilities to address functional T cell avidity. In addition, we discuss the anticipated clinical value of these and other strategies to generate high-avidity T cells.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20122868     DOI: 10.1016/j.molmed.2009.12.004

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  45 in total

1.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

Review 2.  Cellular immunotherapy for malignant gliomas.

Authors:  Yi Lin; Hideho Okada
Journal:  Expert Opin Biol Ther       Date:  2016-07-29       Impact factor: 4.388

3.  Deficiency of lymphotoxin-α does not exacerbate high-fat diet-induced obesity but does enhance inflammation in mice.

Authors:  Nathalie Pamir; Timothy S McMillen; Kimberly A Edgel; Francis Kim; Renée C LeBoeuf
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-02-07       Impact factor: 4.310

4.  Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.

Authors:  D H Aggen; A S Chervin; T M Schmitt; B Engels; J D Stone; S A Richman; K H Piepenbrink; B M Baker; P D Greenberg; H Schreiber; D M Kranz
Journal:  Gene Ther       Date:  2011-07-14       Impact factor: 5.250

Review 5.  Treating cancer with genetically engineered T cells.

Authors:  Tristen S Park; Steven A Rosenberg; Richard A Morgan
Journal:  Trends Biotechnol       Date:  2011-06-12       Impact factor: 19.536

Review 6.  Genetically retargeting CD8+ lymphocyte subsets for cancer immunotherapy.

Authors:  Cameron J Turtle; Stanley R Riddell
Journal:  Curr Opin Immunol       Date:  2011-01-14       Impact factor: 7.486

7.  Influenza virus-specific TCR-transduced T cells as a model for adoptive immunotherapy.

Authors:  Belinda Berdien; Henrike Reinhard; Sabrina Meyer; Stefanie Spöck; Nicolaus Kröger; Djordje Atanackovic; Boris Fehse
Journal:  Hum Vaccin Immunother       Date:  2013-02-21       Impact factor: 3.452

8.  Human antigen-specific regulatory T cells generated by T cell receptor gene transfer.

Authors:  Todd M Brusko; Richard C Koya; Shirley Zhu; Michael R Lee; Amy L Putnam; Stephanie A McClymont; Michael I Nishimura; Shuhong Han; Lung-Ji Chang; Mark A Atkinson; Antoni Ribas; Jeffrey A Bluestone
Journal:  PLoS One       Date:  2010-07-22       Impact factor: 3.240

9.  TCRγ4δ1-engineered αβT cells exhibit effective antitumor activity.

Authors:  Kangxia He; Hongqin You; Yuxia Li; Lianxian Cui; Jianmin Zhang; Wei He
Journal:  Mol Med       Date:  2016-07-26       Impact factor: 6.354

10.  A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.

Authors:  Xiaojun Liu; Raghuveer Ranganathan; Shuguang Jiang; Chongyun Fang; Jing Sun; Soyeon Kim; Kheng Newick; Albert Lo; Carl H June; Yangbing Zhao; Edmund K Moon
Journal:  Cancer Res       Date:  2016-03-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.